Truist Financial Corp Novavax Inc Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$69.73 - $142.9 $115,542 - $236,785	-1,657 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $410,138 - $664,372	-3,048 Reduced 64.78%	1,657 $237,000
Q3 2021 Nov 05, 2021	BUY	$177.8 - $270.58 $462,102 - $703,237	2,599 Added 123.41%	4,705 $975,000
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $49,489 - $105,387	409 Added 24.1%	2,106 $447,000
Q1 2021 May 17, 2021	SELL	$112.98 - $319.93 $484,119 - $1.37 Million	-4,285 Reduced 71.63%	1,697 $308,000
Q4 2020 Feb 18, 2021	BUY	$78.74 - $139.5 $471,022 - $834,489	5,982 New	5,982 $667,000

292

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $630M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.